MX2009008531A - Nitrogen-containing heterocyclyl ketones and methods of use. - Google Patents
Nitrogen-containing heterocyclyl ketones and methods of use.Info
- Publication number
- MX2009008531A MX2009008531A MX2009008531A MX2009008531A MX2009008531A MX 2009008531 A MX2009008531 A MX 2009008531A MX 2009008531 A MX2009008531 A MX 2009008531A MX 2009008531 A MX2009008531 A MX 2009008531A MX 2009008531 A MX2009008531 A MX 2009008531A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- ketones
- nitrogen
- diseases
- containing heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90203007P | 2007-02-16 | 2007-02-16 | |
PCT/US2008/002007 WO2008103277A2 (en) | 2007-02-16 | 2008-02-15 | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009008531A true MX2009008531A (en) | 2009-08-26 |
Family
ID=39563458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009008531A MX2009008531A (en) | 2007-02-16 | 2008-02-15 | Nitrogen-containing heterocyclyl ketones and methods of use. |
Country Status (7)
Country | Link |
---|---|
US (1) | US8314087B2 (en) |
EP (1) | EP2114898A2 (en) |
JP (1) | JP2010519204A (en) |
AU (1) | AU2008219166B2 (en) |
CA (1) | CA2676173A1 (en) |
MX (1) | MX2009008531A (en) |
WO (1) | WO2008103277A2 (en) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101538811B1 (en) | 2007-04-03 | 2015-07-22 | 이 아이 듀폰 디 네모아 앤드 캄파니 | substituted benzene fungicides |
DE102007025718A1 (en) * | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | pyridazinone derivatives |
CN101910159B (en) * | 2007-12-26 | 2013-06-19 | 卫材R&D管理有限公司 | Process for production of heterocycle-substituted pyridine derivative |
DE102008019907A1 (en) * | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | pyridazinone derivatives |
CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
EP2320909B8 (en) | 2008-07-25 | 2016-03-30 | VIIV Healthcare Company | Chemical compounds |
KR101712576B1 (en) | 2008-11-10 | 2017-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | Compounds useful as Inhibitors of ATR kinase |
ES2763540T3 (en) | 2008-12-11 | 2020-05-29 | Viiv Healthcare Co | Intermediates for carbamoylpyridone HIV integrase inhibitors |
BRPI0923217A2 (en) | 2008-12-11 | 2017-05-23 | Glaxosmithkline Llc | processes for the preparation of a pyridone compound, and for the preparation of a crystalline form, compound, salt or a hydrate thereof, crystalline form of a sodium salt or a hydrate thereof, and a pharmaceutical composition. |
PT2376485T (en) | 2008-12-19 | 2018-03-12 | Vertex Pharma | Pyrazine derivatives useful as inhibitors of atr kinase |
TWI518084B (en) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | Process for pyrone and pyridone derivatives |
TW201124078A (en) | 2009-12-22 | 2011-07-16 | Du Pont | Fungicidal 2-(bicyclic aryloxy) carboxamides |
TWI582097B (en) | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | Process for preparing carbamoylpyridone derivatives and intermediates |
WO2011143399A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2011143419A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
CN102947272A (en) | 2010-05-12 | 2013-02-27 | 沃泰克斯药物股份有限公司 | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
WO2011143425A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP5836367B2 (en) | 2010-05-12 | 2015-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Compounds useful as ATR kinase inhibitors |
JP2013529200A (en) | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compounds useful as ATR kinase inhibitors |
CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
WO2011163527A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
JP2013532627A (en) | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | Combination of cMET inhibitor with antibody against HGF and / or cMET |
EP2593107A1 (en) * | 2010-07-12 | 2013-05-22 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
EP2611450A1 (en) * | 2010-08-31 | 2013-07-10 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
TWI526421B (en) | 2010-09-08 | 2016-03-21 | 住友化學股份有限公司 | Method for producing pyridazinone compounds and intermediate thereof |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
KR102061353B1 (en) | 2010-09-10 | 2020-01-02 | 에피자임, 인코포레이티드 | Inhibitors of human ezh2, and methods of use thereof |
WO2012087372A1 (en) | 2010-12-22 | 2012-06-28 | E. I. Du Pont De Nemours And Company | Fungicidal 2-(bicyclic aryloxy)carboxamides |
CN102558147B (en) * | 2010-12-23 | 2014-09-17 | 江苏先声药物研究有限公司 | Compound, and preparation method and application thereof |
AU2012223448B2 (en) | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
KR20140027974A (en) | 2011-04-05 | 2014-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | Aminopyrazine compounds useful as inhibitors of tra kinase |
JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Aryl- or heteroaryl-substituted benzene compounds |
TW201733984A (en) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | Substituted benzene compounds |
JP2014522818A (en) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compounds useful as ATR kinase inhibitors |
JP2014520161A (en) | 2011-06-22 | 2014-08-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compounds useful as ATR kinase inhibitors |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
IN2014KN00943A (en) | 2011-09-30 | 2015-08-21 | Vertex Pharma | |
AU2012315615A1 (en) | 2011-09-30 | 2014-04-17 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CA3089792C (en) | 2011-09-30 | 2023-03-14 | Vertex Pharmaceuticals Incorporated | Treating non-small cell lung cancer with atr inhibitors |
EP2776419B1 (en) | 2011-11-09 | 2016-05-11 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776422A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776420A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2780014A4 (en) * | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2013120104A2 (en) | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
CN104582795B (en) | 2012-04-05 | 2018-04-20 | 沃泰克斯药物股份有限公司 | It can be used as the compound of ATR kinase inhibitors and combinations thereof therapy |
ES2745016T3 (en) | 2012-04-13 | 2020-02-27 | Epizyme Inc | N - ((4,6-Dimethyl-2-oxo-L, 2-dihydropyridin-3-yl) methyl) -5- (ethyl (tetrahydro-2H-pyran-4-yl) amino) -4-methyl hydrobromide -4 '- (morpholinomethyl) - [L, 1'-biphenyl] -3-carboxamide for use in the treatment of a cell proliferative disorder of the hematological system |
UA112897C2 (en) | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | BICYCLIC SUBSTITUTED URATILES AND THEIR APPLICATIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
WO2014055756A1 (en) | 2012-10-04 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
EP3628662A1 (en) | 2012-10-15 | 2020-04-01 | Epizyme, Inc. | Substituted benzene compounds |
EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
DK3486245T3 (en) | 2012-12-07 | 2021-07-19 | Vertex Pharma | 2-AMINO-N- (PIPERIDIN-1-YL-PYRIDIN-3-YL) PYRAZOLO [1,5ALPHA] PYRIMIDINE-3-CARBOXAMIDE INHIBITATING ATR CHINASE |
UA115462C2 (en) | 2012-12-28 | 2017-11-10 | Адама Махтешім Лтд. | -(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1 (2h)-carboxylate derivatives |
AU2013370470B2 (en) * | 2012-12-28 | 2018-05-10 | Adama Makhteshim Ltd. | 1-(substituted-benzoyl)-5-fluoro-4-imino-3-methyl-3,4-dihydropyrimidin-2(1H)-one derivatives |
EP2945634A4 (en) | 2012-12-28 | 2016-05-25 | Dow Agrosciences Llc | N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1 (2h)-carboxamides derivatives |
AU2013370494B2 (en) | 2012-12-31 | 2017-08-17 | Adama Makhteshim Ltd. | 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1H)-one derivatives as fungicides |
JP6669499B2 (en) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | Therapeutic compounds |
JP2016510000A (en) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CN105592888A (en) | 2013-08-06 | 2016-05-18 | 伊美格生物科学公司 | Kdm1a inhibitors for the treatment of disease |
EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
WO2015057626A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | QUINOLINYL MODULATORS OF RORyT |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
PE20161273A1 (en) | 2013-10-16 | 2016-12-18 | Epizyme Inc | SALINE FORM OF HYDROCHLORIDE FOR EZH2 INHIBITION |
JP6445574B2 (en) | 2013-10-18 | 2018-12-26 | セルジーン クオンティセル リサーチ,インク. | Bromodomain inhibitor |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
KR20160099084A (en) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | Crystalline forms of therapeutic compounds and uses thereof |
JP2016535769A (en) | 2013-11-08 | 2016-11-17 | バイエル ファーマ アクチエンゲゼルシャフト | Substituted uracils as chymase inhibitors |
EP3066098A1 (en) | 2013-11-08 | 2016-09-14 | Bayer Pharma Aktiengesellschaft | Substituted uracils and use thereof |
SI3077397T1 (en) | 2013-12-06 | 2020-02-28 | Vertex Pharmaceuticals Inc. | 2-amino-6-fluoro-n-(5-fluoro-pyridin-3-yl)pyrazolo(1,5-a)pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
EP3096761A1 (en) * | 2014-01-24 | 2016-11-30 | Confluence Life Sciences, Inc. | Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases |
WO2015112847A1 (en) * | 2014-01-24 | 2015-07-30 | Confluence Life Sciences, Inc. | Arylpyridinone itk inhibitors for treating inflammation and cancer |
MX2016012808A (en) | 2014-04-02 | 2017-01-05 | Intermune Inc | Anti-fibrotic pyridinones. |
SG10201902206QA (en) | 2014-06-05 | 2019-04-29 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
HUE044280T2 (en) | 2014-06-17 | 2019-10-28 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
US10752640B2 (en) | 2014-08-01 | 2020-08-25 | Nuevolution A/S | Compounds active towards bromodomains |
KR101891933B1 (en) | 2014-08-14 | 2018-08-24 | 에프. 호프만-라 로슈 아게 | Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection |
JP6864953B2 (en) | 2014-12-09 | 2021-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Human monoclonal antibody against AXL |
EP3247353A4 (en) | 2015-01-23 | 2018-07-04 | Confluence Life Sciences, Inc. | Heterocyclic itk inhibitors for treating inflammation and cancer |
KR102626978B1 (en) | 2015-02-12 | 2024-01-18 | 이마고 바이오사이언시즈 인코포레이티드 | Kdm1a inhibitors for the treatment of disease |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
CA2990791A1 (en) * | 2015-06-25 | 2016-12-29 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for fibrosis |
AU2016297786A1 (en) | 2015-07-24 | 2018-02-08 | Noeleen Melody | Quinstatin compounds |
IL257340B2 (en) * | 2015-08-12 | 2023-10-01 | Neomed Inst | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
KR20180054657A (en) | 2015-09-30 | 2018-05-24 | 버텍스 파마슈티칼스 인코포레이티드 | Methods of treating cancer with a combination of DNA damaging agents and ATR inhibitors |
US20190112317A1 (en) | 2015-10-05 | 2019-04-18 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
EP3362442B1 (en) | 2015-10-14 | 2020-01-29 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as apj agonists |
UY37026A (en) | 2015-12-16 | 2017-06-30 | Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware | HETEROARILHYDROXIPIRIMIDINONAS AS APJ RECEIVER AGONISTS |
CA3018346A1 (en) | 2016-03-24 | 2017-09-28 | Bristol-Myers Squibb Company | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
US11390590B2 (en) | 2016-08-16 | 2022-07-19 | Imago Biosciences, Inc. | Methods and processes for the preparation of KDM1A inhibitors |
CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324251A1 (en) | 2016-09-08 | 2019-03-21 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN109843870A (en) | 2016-10-19 | 2019-06-04 | 星座制药公司 | The synthesis of EZH2 inhibitor |
CA3041676A1 (en) * | 2016-10-26 | 2018-05-03 | Daniel Parks | Pyridazine derivatives, compositions and methods for modulating cftr |
RS61126B1 (en) * | 2016-10-27 | 2020-12-31 | Fujian Cosunter Pharmaceutical Co Ltd | Pyridone compound as c-met inhibitor |
US10316038B2 (en) | 2017-01-25 | 2019-06-11 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer |
US11632954B2 (en) | 2017-07-17 | 2023-04-25 | Adama Makhteshim Ltd. | Polymorphs of 5-fluoro-4-imino-3-methyl-1 -tosyl-3,4-dihydropyrimidin-2-one |
CN110117278B (en) * | 2018-02-07 | 2022-07-19 | 石家庄以岭药业股份有限公司 | Alkoxybenzo five-membered (six-membered) heterocyclic amine compound and pharmaceutical application thereof |
JP7450559B2 (en) * | 2018-05-11 | 2024-03-15 | イマーゴ バイオサイエンシーズ インコーポレイテッド | KDM1A inhibitors for the treatment of diseases |
JP2021527636A (en) * | 2018-06-04 | 2021-10-14 | オハイオ・ステイト・イノベーション・ファウンデーション | EAAT2 activator and its usage |
CN113272280A (en) | 2018-11-06 | 2021-08-17 | 艾知怀斯治疗学公司 | Pyridazinone compound and use thereof |
DK3877376T3 (en) | 2018-11-06 | 2023-10-02 | Edgewise Therapeutics Inc | Pyridazinone compounds and uses thereof |
CN111393375A (en) * | 2020-04-07 | 2020-07-10 | 中国药科大学 | Nitrogen-substituted hexabasic aromatic heterocyclic ketone compound and pharmaceutical composition, preparation method and application thereof |
EP4149621A1 (en) * | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
CN115872976A (en) * | 2022-12-30 | 2023-03-31 | 中国药科大学 | Quinoline derivative, pharmaceutical composition containing quinoline derivative and application of quinoline derivative |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3009A (en) * | 1843-03-21 | Lard-lamp | ||
US3956287A (en) * | 1973-11-07 | 1976-05-11 | Richardson-Merrell Inc. | 7-[(2-Oxo-1-pyridinyl)acylamino]cephalosporin derivatives |
CH629240A5 (en) * | 1976-09-02 | 1982-04-15 | Henkel Kgaa | AGENT FOR COLORING MATERIAL CONTAINING KERATINE. |
EP0092520B1 (en) * | 1982-04-15 | 1986-11-12 | Sandoz Ag | Basic compounds, their preparation and their use |
US4673735A (en) * | 1982-04-15 | 1987-06-16 | Sandoz Ltd. | Azo compounds having at least one 6-hydroxypyrid-2-one coupling component radical metal complexes thereof and intermediates therefor |
JP2762522B2 (en) | 1989-03-06 | 1998-06-04 | 藤沢薬品工業株式会社 | Angiogenesis inhibitor |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
US5892112A (en) | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
FR2670208B1 (en) | 1990-12-07 | 1993-08-13 | Pf Medicament | DERIVATIVES OF PHENYL-1 DIHYDRO 1-4 ARYLALCOYLAMINO-3 OXO-4 PYRIDAZINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. |
CZ403592A3 (en) * | 1992-02-20 | 1993-12-15 | Hoechst Ag | Arylcarbonylaminoalkyldihydrooxopyridines, process of their preparation and their use |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
PT669929E (en) | 1992-11-13 | 2007-04-30 | Immunex Corp | Elk ligand, a cytokine |
PT672031E (en) | 1992-12-02 | 2003-06-30 | Pfizer | DIETERES OF CATECOL AS SELECTIVE INHIBITORS OF PDE IV |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5516658A (en) | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
JPH09512167A (en) | 1994-04-15 | 1997-12-09 | アムジエン・インコーポレーテツド | HEK5, HEK7, HEK8, HEK11, novel EPH-like receptor protein tyrosine kinase |
US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
US5919905A (en) | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
CO4950519A1 (en) | 1997-02-13 | 2000-09-01 | Novartis Ag | PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION |
RS49779B (en) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
DE69940808D1 (en) | 1998-03-04 | 2009-06-10 | Bristol Myers Squibb Co | HETEROCYCLES SUBSTITUTED IMIDAZOPYRAZINES AS PROTEIN TYROSINE KINASE INHIBITORS |
EP1082305A4 (en) | 1998-05-29 | 2001-09-26 | Sugen Inc | Pyrrole substituted 2-indolinone protein kinase inhibitors |
UA60365C2 (en) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal |
CA2336848A1 (en) | 1998-07-10 | 2000-01-20 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
EP1109555A4 (en) | 1998-08-31 | 2001-11-21 | Merck & Co Inc | Novel angiogenesis inhibitors |
WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
TW506993B (en) * | 1999-03-15 | 2002-10-21 | Ciba Sc Holding Ag | Reactive dyes, processes for their preparation and process for dyeing or printing a fibre material |
DE60010362T2 (en) * | 1999-03-30 | 2005-05-04 | Ciba Specialty Chemicals Holding Inc. | Reactive dyes, process for their preparation and their use |
AU766081B2 (en) | 1999-03-30 | 2003-10-09 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
DK1187918T4 (en) | 1999-06-07 | 2009-02-23 | Immunex Corp | Tek antagonists |
SI1676845T1 (en) | 1999-11-05 | 2008-10-31 | Astrazeneca Ab | New quinazoline derivatives |
PT1233943E (en) | 1999-11-24 | 2011-09-01 | Sugen Inc | Ionizable indolinone derivatives and their use as ptk ligands |
US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
AU2001247219B2 (en) | 2000-02-25 | 2007-01-04 | Immunex Corporation | Integrin antagonists |
EP1270577B1 (en) * | 2000-03-23 | 2006-12-06 | Takeda Pharmaceutical Company Limited | Furoisoquinoline derivatives, process for producing the same and use thereof |
JP2001335579A (en) * | 2000-03-23 | 2001-12-04 | Takeda Chem Ind Ltd | Furoisoquinoline derivative, method for producing the same and use |
US6630500B2 (en) | 2000-08-25 | 2003-10-07 | Cephalon, Inc. | Selected fused pyrrolocarbazoles |
DE122010000038I1 (en) | 2000-12-21 | 2011-01-27 | Glaxosmithkline Llc | PYRIMIDINAMINES AS ANGIOGENESIS MODULATORS |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
ES2195785B1 (en) * | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US7560558B2 (en) * | 2002-08-23 | 2009-07-14 | Kirin Beer Kabushiki Kaisha | Compound having TGFβ inhibitory activity and medicinal composition containing the same |
WO2004037807A2 (en) * | 2002-10-22 | 2004-05-06 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
WO2005000818A1 (en) * | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
RU2339381C2 (en) * | 2004-02-09 | 2008-11-27 | Ниссан Кемикал Индастриз, Лтд. | Preventer of blood vessels intima hyperplasia |
US20080161305A1 (en) | 2005-04-06 | 2008-07-03 | Exelixis, Inc. | C-Met Modulators and Methods of Use |
JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
CA2630233A1 (en) * | 2005-12-05 | 2007-06-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors |
CA2637392A1 (en) * | 2006-01-23 | 2007-07-26 | Crystalgenomics, Inc. | Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same |
RU2008150485A (en) * | 2006-05-22 | 2010-06-27 | Янссен Фармацевтика Н.В. (Be) | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINAL PRODUCT |
DE102006037478A1 (en) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2- (Heterocyclylbenzyl) -pyridazinone derivatives |
WO2008038841A1 (en) * | 2006-09-30 | 2008-04-03 | Japan Tobacco Inc. | Thiadiazolone derivative and use thereof |
MX2009006312A (en) * | 2006-12-14 | 2009-08-07 | Astellas Pharma Inc | Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents. |
US8163779B2 (en) * | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
TWI407960B (en) * | 2007-03-23 | 2013-09-11 | Jerini Ag | Small molecule bradykinin b2 receptor modulators |
US8258134B2 (en) * | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
TWI367598B (en) * | 2008-06-23 | 2012-07-01 | Ind Tech Res Inst | Antenna radome |
-
2008
- 2008-02-15 CA CA002676173A patent/CA2676173A1/en not_active Abandoned
- 2008-02-15 EP EP08725619A patent/EP2114898A2/en not_active Withdrawn
- 2008-02-15 MX MX2009008531A patent/MX2009008531A/en active IP Right Grant
- 2008-02-15 US US12/070,309 patent/US8314087B2/en active Active
- 2008-02-15 WO PCT/US2008/002007 patent/WO2008103277A2/en active Application Filing
- 2008-02-15 AU AU2008219166A patent/AU2008219166B2/en not_active Ceased
- 2008-02-15 JP JP2009549625A patent/JP2010519204A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2008219166A1 (en) | 2008-08-28 |
EP2114898A2 (en) | 2009-11-11 |
US8314087B2 (en) | 2012-11-20 |
US20080280917A1 (en) | 2008-11-13 |
CA2676173A1 (en) | 2008-08-28 |
WO2008103277A3 (en) | 2009-04-16 |
WO2008103277A2 (en) | 2008-08-28 |
JP2010519204A (en) | 2010-06-03 |
AU2008219166B2 (en) | 2013-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009008531A (en) | Nitrogen-containing heterocyclyl ketones and methods of use. | |
UA98373C2 (en) | Condensed heterocyclic compounds and use thereof as c-met inhibitors | |
MY167135A (en) | Fused heterocyclic derivatives and methods of use | |
TW200716596A (en) | Substituted amide derivatives and methods of use | |
TNSN06228A1 (en) | Compounds and methods of use | |
WO2008079291A3 (en) | Substituted heterocycles and methods of use | |
MX2009006543A (en) | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer. | |
WO2008086014A3 (en) | Bis-aryl amide derivatives useful for the treatment of cancer | |
WO2007005668A3 (en) | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer | |
WO2007048070A3 (en) | Pyrrolo-pyridine derivatives for the treatment of cancer diseases | |
ATE404552T1 (en) | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE | |
UA101493C2 (en) | Azetidine and cyclobutane derivatives as jak inhibitors | |
MX2009012168A (en) | Pyrrolopyridine derivatives and their use as bace inhibitors. | |
IN2012DN00971A (en) | ||
IL172419A0 (en) | Piperazine derivatives and methods of use | |
MX2009010407A (en) | Fluorinated derivatives of deferiprone. | |
MX2011013032A (en) | Inhibitors of phosphatidylinositol 3-kinase. | |
MX2012001134A (en) | Compositions and methods for inhibition of the jak pathway. | |
ATE540038T1 (en) | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | |
MX2013002118A (en) | Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators. | |
MX2011008645A (en) | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase. | |
IN2013DN02555A (en) | ||
MX2010004620A (en) | Benzomorpholine derivatives and methods of use. | |
MX2013002295A (en) | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators. | |
EP2464355A4 (en) | Substituted triazolophthalazine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |